Evolus, Inc. (LON: 0K16)
London
· Delayed Price · Currency is GBP · Price in USD
14.18
+0.51 (3.72%)
Jan 22, 2025, 6:49 PM BST
Evolus Revenue
Evolus had revenue of $61.09M USD in the quarter ending September 30, 2024, with 22.12% growth. This brings the company's revenue in the last twelve months to $248.33M, up 34.43% year-over-year. In the year 2023, Evolus had annual revenue of $202.09M with 35.98% growth.
Revenue (ttm)
$248.33M
Revenue Growth
+34.43%
P/S Ratio
n/a
Revenue / Employee
$909.62K
Employees
273
Market Cap
726.48M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Evolus News
- 14 days ago - Evolus Inc (EOLS) Shares Gap Down to $10.33 on Jan 8 - GuruFocus
- 26 days ago - Evolus Inc (EOLS) Trading Down 3.61% on Dec 27 - GuruFocus
- 5 weeks ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha
- 2 months ago - Evolus Reports Third Quarter 2024 Results - Business Wire
- 2 months ago - Evolus to Participate in Stifel 2024 Healthcare Conference - Business Wire
- 2 months ago - Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation - Business Wire
- 3 months ago - Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers - Business Wire